Invitrogen Reaches Settlement with Bio-Rad in Patent Cases; Inks Synthetic Gene Alliance | GenomeWeb
This article has been corrected from an earlier version to reflect the settlement of both suits, not just one, between Invitrogen and Bio-Rad.
Invitrogen and Bio-Rad Laboratories have reached settlements in two patent infringement suits filed by Invitrogen alleging that some of Bio-Rad’s products infringed upon certain Invitrogen patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.